Skip to content

Logos Global Management LP 13F Holdings · Q2 2026

Logos Global Management LP reported 68 securities worth $2.32B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: ERAS (9.58%), ABVX (5.87%), RVMD (5.64%). Among its top 25 positions this quarter: 6 new, 13 added, 5 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1ERASERASCA INC$222.6M9.58%12.2MAdded
2ABVXABIVAX SA$136.5M5.87%1.0MAdded
3RVMDREVOLUTION MEDICINES INC$131.1M5.64%700,000Trimmed
4IDYAIDEAYA BIOSCIENCES INC$111.8M4.81%3.0MTrimmed
5BNTXBIONTECH SE$94.4M4.07%1.0MNew
6VERAVERA THERAPEUTICS INC$94.4M4.06%2.2MNew
7TNGXTANGO THERAPEUTICS INC$89.1M3.84%2.9MTrimmed
8PRAXPRAXIS PRECISION MEDICINES I$87.0M3.75%260,000Trimmed
9CLDXCELLDEX THERAPEUTICS INC NEW$78.1M3.36%2.1MAdded
10DNTHDIANTHUS THERAPEUTICS INC$78.0M3.36%800,000Added
11CGONCG ONCOLOGY INC$71.0M3.06%1.0MAdded
12IRONDISC MEDICINE INC$64.0M2.76%875,000Added
13MAZEMAZE THERAPEUTICS INC$57.7M2.49%1.9MAdded
14DYNDYNE THERAPEUTICS INC$56.6M2.44%2.5MAdded
15MLTXMOONLAKE IMMUNOTHERAPEUTICS$52.1M2.24%2.7MAdded
16OCULOCULAR THERAPEUTIX INC$52.0M2.24%5.3MAdded
17DSGNDESIGN THERAPEUTICS INC$43.4M1.87%3.0MAdded
18OLMAOLEMA PHARMACEUTICALS INC$40.1M1.73%3.2MHold
19BLTEBELITE BIO INC$38.5M1.66%250,000New
20ACHVACHIEVE LIFE SCIENCE INC$35.4M1.53%5.4MNew
21TRVITREVI THERAPEUTICS INC$35.1M1.51%1.9MTrimmed
22AVBPARRIVENT BIOPHARMA INC$34.7M1.50%1.0MAdded
23COGTCOGENT BIOSCIENCES INC$34.8M1.50%900,000New
24CBIOCRESCENT BIOPHARMA INC.$34.2M1.47%1.9MAdded
25CMPSCOMPASS PATHWAYS PLC$31.8M1.37%2.2MNew

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR